公开(公告)号：US20150251999A1

公开(公告)日：2015-09-10

申请号：US14716361

申请日：2015-05-19

Applicant: Pfizer Inc.

Inventor： Anthony Michael Campeta ,  Joseph Francis Krzyzaniak ,  Jason Albert Leonard

IPC: C07D207/34 ,  C07D295/027 ,  C07C215/08 ,  C07C211/07 ,  C07C229/26

CPC classification number: C07D207/34 ,  C07C211/07 ,  C07C215/08 ,  C07C229/26 ,  C07D295/027 ,  C07D295/037

Abstract: Novel salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid characterized by their X-ray powder diffraction pattern and solid-state NMR spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and Alzheimer's Disease.

Abstract translation: [R-（R *，R *）] - 2-（4-氟苯基） - ，b-的新型盐形式，δ-二羟基-5-（1-甲基乙基）-3-苯基-4 - [（苯基氨基）羰基 ] -1H-吡咯-1-庚酸，其特征在于它们的X射线粉末衍射图和固态NMR光谱，以及其制备方法和药物组合物，其可用作治疗高脂血症的药剂 ，高胆固醇血症，骨质疏松症，良性前列腺增生症和阿尔茨海默病。

公开(公告)号：US20170190663A1

公开(公告)日：2017-07-06

申请号：US15468419

申请日：2017-03-24

Applicant: Pfizer Inc.

Inventor： Anthony Michael Campeta ,  Joseph Francis Krzyzaniak ,  Jason Albert Leonard

IPC: C07D207/34 ,  C07C229/26 ,  C07D295/027 ,  C07C211/07

CPC classification number: C07D207/34 ,  C07C211/07 ,  C07C215/08 ,  C07C229/26 ,  C07D295/027 ,  C07D295/037

Abstract: Novel salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid characterized by their X-ray powder diffraction pattern and solid-state NMR spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and Alzheimer's Disease.

公开(公告)号：US20140005384A1

公开(公告)日：2014-01-02

申请号：US14016839

申请日：2013-09-03

Applicant: Pfizer Inc.

Inventor： Anthony Michael Campeta ,  Joseph Francis Krzyzaniak ,  Jason Albert Leonard

IPC: C07D295/037 ,  C07D207/34

CPC classification number: C07D207/34 ,  C07C211/07 ,  C07C215/08 ,  C07C229/26 ,  C07D295/027 ,  C07D295/037

Abstract: Novel salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid characterized by their X-ray powder diffraction pattern and solid-state NMR spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and Alzheimer's Disease.

Abstract translation: [R-（R *，R *）] - 2-（4-氟苯基） - ，δ-二羟基-5-（1-甲基乙基）-3-苯基-4 - [（苯基氨基）羰基] 描述了其X-射线粉末衍射图和固态NMR光谱表征的1H-吡咯-1-庚酸，以及其制备方法和药物组合物，其可用作治疗高脂血症的药剂， 高胆固醇血症，骨质疏松症，良性前列腺增生症和阿尔茨海默病。

公开(公告)号：US20160185720A1

公开(公告)日：2016-06-30

申请号：US15061931

申请日：2016-03-04

Applicant: Pfizer Inc.

Inventor： Anthony Michael Campeta ,  Joseph Francis Krzyzaniak ,  Jason Albert Leonard

IPC: C07D207/34 ,  C07C215/08 ,  C07C229/26 ,  C07D295/027 ,  C07C211/07

CPC classification number: C07D207/34 ,  C07C211/07 ,  C07C215/08 ,  C07C229/26 ,  C07D295/027 ,  C07D295/037

Abstract: Novel salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid characterized by their X-ray powder diffraction pattern and solid-state NMR spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and Alzheimer's Disease.

公开(公告)号：US20140336395A1

公开(公告)日：2014-11-13

申请号：US14340067

申请日：2014-07-24

Applicant: Pfizer Inc.

Inventor： Anthony Michael Campeta ,  Joseph Francis Krzyzaniak ,  Jason Albert Leonard

IPC: C07D207/34 ,  C07C215/08 ,  C07D295/027 ,  C07C211/07 ,  C07C229/26

CPC classification number: C07D207/34 ,  C07C211/07 ,  C07C215/08 ,  C07C229/26 ,  C07D295/027 ,  C07D295/037

Abstract: Novel salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid characterized by their X-ray powder diffraction pattern and solid-state NMR spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and Alzheimer's Disease.

Abstract translation: [R-（R *，R *）] - 2-（4-氟苯基） - ，b-的新型盐形式，δ-二羟基-5-（1-甲基乙基）-3-苯基-4 - [（苯基氨基）羰基 ] -1H-吡咯-1-庚酸，其特征在于它们的X射线粉末衍射图和固态NMR光谱，以及其制备方法和药物组合物，其可用作治疗高脂血症的药剂 ，高胆固醇血症，骨质疏松症，良性前列腺增生症和阿尔茨海默病。

公开(公告)号：US08822703B2

公开(公告)日：2014-09-02

申请号：US14016839

申请日：2013-09-03

Applicant: Pfizer Inc.

Inventor： Joseph Francis Krzyzaniak ,  Jason Albert Leonard

IPC: C07D207/00

CPC classification number: C07D207/34 ,  C07C211/07 ,  C07C215/08 ,  C07C229/26 ,  C07D295/027 ,  C07D295/037

Abstract: Novel salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid characterized by their X-ray powder diffraction pattern and solid-state NMR spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and Alzheimer's Disease.

Abstract translation: [R-（R *，R *）] - 2-（4-氟苯基） - ，b-的新型盐形式，δ-二羟基-5-（1-甲基乙基）-3-苯基-4 - [（苯基氨基）羰基 ] -1H-吡咯-1-庚酸，其特征在于它们的X射线粉末衍射图和固态NMR光谱，以及其制备方法和药物组合物，其可用作治疗高脂血症的药剂 ，高胆固醇血症，骨质疏松症，良性前列腺增生症和阿尔茨海默病。

公开(公告)号：US09908850B2

公开(公告)日：2018-03-06

申请号：US15468419

申请日：2017-03-24

Applicant: Pfizer Inc.

Inventor： Joseph Francis Krzyzaniak ,  Jason Albert Leonard

IPC: C07D207/34 ,  C07C211/07 ,  C07C229/26 ,  C07D295/027

CPC classification number: C07D207/34 ,  C07C211/07 ,  C07C215/08 ,  C07C229/26 ,  C07D295/027 ,  C07D295/037

Abstract: Novel salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid characterized by their X-ray powder diffraction pattern and solid-state NMR spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and Alzheimer's Disease.

公开(公告)号：US09637449B2

公开(公告)日：2017-05-02

申请号：US15061931

申请日：2016-03-04

Applicant: Pfizer Inc.

Inventor： Joseph Francis Krzyzaniak ,  Jason Albert Leonard

IPC: C07D207/34 ,  C07D295/037 ,  C07C211/07 ,  C07C215/08 ,  C07C229/26 ,  C07D295/027

CPC classification number: C07D207/34 ,  C07C211/07 ,  C07C215/08 ,  C07C229/26 ,  C07D295/027 ,  C07D295/037

Abstract: Novel salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid characterized by their X-ray powder diffraction pattern and solid-state NMR spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and Alzheimer's Disease.

公开(公告)号：US09309195B2

公开(公告)日：2016-04-12

申请号：US14716361

申请日：2015-05-19

Applicant: Pfizer Inc.

Inventor： Joseph Francis Krzyzaniak ,  Jason Albert Leonard

IPC: C07D207/34 ,  C07D295/037 ,  C07C211/07 ,  C07C215/08 ,  C07C229/26 ,  C07D295/027

CPC classification number: C07D207/34 ,  C07C211/07 ,  C07C215/08 ,  C07C229/26 ,  C07D295/027 ,  C07D295/037

Abstract: Novel salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid characterized by their X-ray powder diffraction pattern and solid-state NMR spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and Alzheimer's Disease.

Abstract translation: [R-（R *，R *）] - 2-（4-氟苯基） - ，b-的新型盐形式，δ-二羟基-5-（1-甲基乙基）-3-苯基-4 - [（苯基氨基）羰基 ] -1H-吡咯-1-庚酸，其特征在于它们的X射线粉末衍射图和固态NMR光谱，以及其制备方法和药物组合物，其可用作治疗高脂血症的药剂 ，高胆固醇血症，骨质疏松症，良性前列腺增生症和阿尔茨海默病。

公开(公告)号：US09073852B2

公开(公告)日：2015-07-07

申请号：US14340067

申请日：2014-07-24

Applicant: Pfizer Inc.

Inventor： Joseph Francis Krzyzaniak ,  Jason Albert Leonard

IPC: C07D207/00 ,  C07D207/34 ,  C07D295/037 ,  C07C211/07 ,  C07C215/08 ,  C07C229/26 ,  C07D295/027

CPC classification number: C07D207/34 ,  C07C211/07 ,  C07C215/08 ,  C07C229/26 ,  C07D295/027 ,  C07D295/037

Abstract: Novel salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid characterized by their X-ray powder diffraction pattern and solid-state NMR spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and Alzheimer's Disease.

Abstract translation: [R-（R *，R *）] - 2-（4-氟苯基） - ，b-的新型盐形式，δ-二羟基-5-（1-甲基乙基）-3-苯基-4 - [（苯基氨基）羰基 ] -1H-吡咯-1-庚酸，其特征在于它们的X射线粉末衍射图和固态NMR光谱，以及其制备方法和药物组合物，其可用作治疗高脂血症的药剂 ，高胆固醇血症，骨质疏松症，良性前列腺增生症和阿尔茨海默病。